{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "15da34ff301a782951e134b2f8093814",
    "title": "Investment Implications",
    "source_uri": "2025-08-28/ARGX O whys there still much more to play for 885 ARGX O whys there still much more to play for 885_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T11:28:37.393396",
      "extracted_at": "2025-10-26T11:28:37.393404"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 25,
        "successful_pages": 25,
        "date": "2025-08-28",
        "publication": "2025-08-28",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.028090688720946777
        },
        "input_relative_path": "2025-08-28"
      }
    }
  },
  "passages": [
    {
      "passage_id": "3d51f63e50602bec",
      "text": "European Biopharmaceuticals",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ad4f7cde257cce94",
      "text": "**ARGX (0): why's there still much more to play for (£885)?**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d854ae08bc0ef2e7",
      "text": "Our upgraded EPS forecasts are upto 25% &gt; consensus (Bloomberg) as we think Myasthenia Gravis (MG; neuromuscular autoimmune disease) market expansion and Vygvart life cycle management and both underappreciated. The risks to our new £885 PT (up by 29%) are also positively skewed (+117% if ARGX hits its 2030 guidance of 50k patients treated with its drugs vs -49% if the entire pipeline fails). Hence, we identify eight potential R&D catalysts pre year-end 2028. What's more, our new £885 PT implies a PE30 of 13x for a 20% premium to peers which is robust on our regression analysis due to ARGX's leading prospects.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9372a1388d4a2ce7",
      "text": "**Why are the risks positively skewed?** Our bull case assumes risk adjusted sales contributions (for current growth driver Vygvart and the next most advanced drug empasibprubart ('empa')) in all the diseases in which ARGX is running registrational trials. This scenario thus discounts 39k ARGX treated patients in 2030 and implies upside to the share price (s/p) and our PT of 126% and 56% respectively. But we also calculate that the 2030 guidance of 50k ARGX treated patients implies the shares would be worth £1,920.Conversely, in our bear case if Vygvart only generates sales in its two current segments, we derive only 27k ARGX treated patients. In this instance, the downside to the s/p and our PT would be 26% and 49% respectively. But considering ARGX's excellent execution since the 4Q23 pipeline nadir we believe that this bearish scenario is extreme.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3c88cfd418207dba",
      "text": "**What's changed and why we do forecast so much upside surprise?** We're raising our 2025-2027e EPS by 27-130% due to higher than expected US Vygvart volumes April-July 2025 driven by the better launch of the new, simpler delivery device (Pre Filled Syringe;allows for home use without a nurse). Our new 2025-2034e EPS are thus now upto 25% &gt;consensus as we don't believe that 'the market' is adequately discounting the potential for Vygvart life cycle management and ARGX's guidance for new innovation to expand the number of MG treated patients in the US by 25k between 2022 and 2030 (Exhibit 6).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2ba4a5aff901ac08",
      "text": "**How do we calculate our Price Target (PT) and why do we think the stock is cheap?** Our PT is still the average of '27-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our PT is increasing by 29% to £885 as our upgrades are augmented by peer group multiple expansion and rolling over.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9b27b49948af1af3",
      "text": "Adjusted EPSF24AF25EF26EFinancialsF24AF25EF26ECAGRValuation MetricsF24AF25EF26EARGX.BB (USD)12.7817.7821.83Reported EPS12.7817.7821.83--Adjusted P/E (x)54.639.231.9OLD--7.7411.79",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "704dcd5a22bffb9a",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4d063ba6ef2e26df",
      "text": "**See the Disclosure Appendix of this report for required disclosures, analyst certifications and other** **important information. Alternatively, visit our Global Research Disclosure Website.**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9d6f953df48c5276",
      "text": "First Published: 28 Aug 2025 04:00 UTC Completion Date: 27 Aug 2025 15:17 UTC",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d901aa1728b8caa1",
      "text": "Price Target Upgrade",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "da5411334fc83345",
      "text": "**Florent Cespedes**",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cea19676597adb4a",
      "text": "Close Date 26 Aug 2025",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "be31ff3fa081f3b2",
      "text": "ARGX.BB Close Price (EUR) 598.60",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cd1478f318144d41",
      "text": "Price Target (EUR) 885.00",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6b29b66a796579c0",
      "text": "Upside/(Downside) 48%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "6bfa251d1a409cd5",
      "text": "52-Week Range 658.00/456.30",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "339bc01c633e22cf",
      "text": "Market Cap (EUR) (M) 37,528",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "afde73f742c3ca19",
      "text": "Performance YTD 1M 6M 12M",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e55bd918668732fa",
      "text": "Absolute (%) 2.2 21.7 0.3 33.2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5446dd453ea8b06e",
      "text": "EDM (%) 22.1 0.9 10.4 10.8",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d21c8c7331be08ad",
      "text": "Relative (%) (19.9) 20.8 (10.2) 22.4",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "70250296e30eb6e9",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dd62232b6b1dc996",
      "text": "Price Performance, 1YR",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "320e200742303119",
      "text": "-ARGX.BB -Bloomberg Europe Developed Markets Large & Mid Cap Price Return Index",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1ddfb2eaebcffb32",
      "text": "Adjusted EPSF24AF25EF26EFinancialsF24AF25EF26ECAGRValuation MetricsF24AF25EF26EARGX.BB (USD)12.7817.7821.83Reported EPS12.7817.7821.83--Adjusted P/E (x)54.639.231.9OLD--7.7411.79",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f58cc2b51deae96f",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b11a086cfcde64ef",
      "text": "EXHIBIT 1: Argenx: changes to Bernstein EPS estimates and comparison to consensus (\\$)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "178bcb4548ec3faa",
      "text": "2025e2026e2027e2028e2029e2030e2031e2032e2033e2034eBernstein old7.7411.7926.1746.1962.6273.9883.3689.8094.2196.56Bernstein new17.7821.8333.1350.4765.0577.0187.8895.29101.24106.40% change130%85%27%9%4%4%5%6%7%10%Consensus15.4825.0234.3645.2651.9863.1472.9681.4590.7389.54% variance15%-13%-4%12%25%22%20%17%12%19%",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1d560acfee2e8349",
      "text": "Source: Bernstein estimates and analysis, Bloomberg for consensus",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2a373443525e805d",
      "text": "We are increasing our 2025- 2027 EPS forecasts by 27- 130% (Exhibit 1) due to the higher than expected realized Vygvart volumes in the US in its two FDA approved indications (Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)) between April and July 2025 (Exhibit 2). We believe that a major driver of this is the better launch of the Prefilled Syringe (PFS) delivery device of the subcutaneous (injection under the skin) formulation of Vygvart (brand name is Hytruio; Exhibit 5).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5edb7781b0da289c",
      "text": "We're also raising our EBIT margin estimates over this same period by 400- 1500 basis points as we now expect better fixed cost absorption. Moreover, we don't believe that material new SG&A investments will be required until 2027/2028 when Argenx might launch Vygvart in two therapeutic areas where it has no existing presence (Thyroid Eye Disease (TED) and Sjoegren's).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "05dc64d5b5d3f972",
      "text": "We are also upgrading our EPS projections even though the US price of Vygvart (net of discounts and rebates) was lower than we expected in 2Q25 due to mix (ie higher discounts on Hytruio than the original intravenous version of Vygvart (Exhibit 4)).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1b9e64802bd9c376",
      "text": "Overall, the increases to our projections now mean that we expect Argenx's EPS to increase seven- fold between 2026 and 2031 vs a four- fold increase over this period previously.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8f5c5970f1c73e5e",
      "text": "EXHIBIT 2: Vygvart US total prescription (Trx) volumes",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "bc9e3d4e0cf36d11",
      "text": "Source: Bernstein analysis, Bloomberg consensus",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "cd15d3d5708aee94",
      "text": "EXHIBIT 3: Argenx consensus EPS estimates (\\$)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d69f77f7cfa4c6ff",
      "text": "Source: Bernstein analysis, Bloomberg consensus",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c7b205a4b071044b",
      "text": "EXHIBIT 4: Vyvgart delivered by intravenous infusion (which was the first formulation to receive FDA approval in 2022) is more time consuming and expensive to administer than....",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "746b8d2143216854",
      "text": "Source: www.Vyvgart.com",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "baae2130598ea0ba",
      "text": "EXHIBIT 5: ....Hytrolu (under the skin injection) via a butterfly syringe (pictured here). And the Hytrolu prefilled syringe (FDA approved on 14/4/25) is even easier to use than the Hytrolu butterfly syringe",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d98c18292192576d",
      "text": "Source: www.Vyvgart.com",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1900c1feef412a50",
      "text": "During its 16/7/25 CMD Argenx introduced its vision for the Myasthenia Gravis (MG) market to expand \\(>3x\\) between 2022 and 2030 (Exhibit 6). Management expects this to be partly driven by the approval of Vyvgart in two new subpopulations (seronegative and ocular patients - Exhibit 13). But the company believes that a more important driver of market expansion will be the launches of new biologics (protein- based drug) into this segment.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "6478a01e0a4587e0",
      "text": "We believe that Argenx's view on market expansion is robust because a high- volume US MG physician told us in 3Q24 that he can't always secure Vyvgart reimbursement because it's too time- consuming. Nonetheless, this doctor believes that more pharmaceutical innovation in MG will facilitate patient access to Vyvgart because the new biopharma companies entering this category will break- down the commercial barriers and ease the bottlenecks. We also note that during its 2Q25 results call AstraZeneca (which is already present in the MG market with its C5 inhibitor Ultomiris) indicated that it expects the percentage of global patients treated with branded medicines to increase from \\(",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7d4476f298901806",
      "text": "EXHIBIT 6: Argenx's view of the growth (2022- 2030) in the US addressable MG patient population",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b34ccae57cba7bd1",
      "text": "MG = Myasthenia Gravis Source: Argenx 2Q25 results slides",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "fed064218560277f",
      "text": "We acknowledge that there have recently been upgrades to the consensus EPS forecasts for Argenx (Exhibit 3). Nonetheless, our new EPS estimates for this stock are upto \\(25\\%\\) ahead of Bloomberg consensus (Exhibit 1) for two key reasons:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "84dcb57662849136",
      "text": "1/ Vygart life cycle management: following a recent conversation with IR, we understand that lots of sell side analysts are still only including Vygart's use in MG and CIDP in their group revenues forecasts. However, to be consistent with the rest of our EU biopharma coverage, our group sales forecasts continue to include risk adjusted contributions for all the segments in which Argenx is conducting registrational trials (Exhibit 9; Exhibit 13).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7d61ee0e353b53a2",
      "text": "2/ MG market expansion: in our view the 2Q25 results demonstrated that new innovation (ie the Hytulo Pre Filled Syringe) is now expanding the market for branded biologic use in the US MG market (Exhibit 2). We also believe that the projections for MG market expansion which AstraZeneca published with its 2Q25 results are credible considering its solid execution on the launch of Ultomiris in this disease (Exhibit 7). Our Argenx forecasts thus now assume that between 2022 and 2030 the total addressable MG population in the US increases by 8k patients (Exhibit 9). This compares to",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "4da9d467a92f00a9",
      "text": "- All primary and secondary endpoints met",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "88ff2586f2f5e9d6",
      "text": "- Statistically significant and clinically meaningful improvement in MG-ADL",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "16960e252e541973",
      "text": "- Rapid, complete and sustained complement inhibition, translating to improvements in patient outcomes",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b1939ae5e10febf3",
      "text": "Global gMG market dynamics",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "ae397af6cdbba53f",
      "text": "Patients on self- admin. medicines by 20302",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8eabb24fcdf7b3d5",
      "text": "(1) AZN aim to have both the gefurulimab auto-injector and pre-filled syringe options approved and available (2) Internal AZN estimates and forecasts Source: AstraZeneca 2025 results presentation",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2ed7532e270a8e7e",
      "text": "EXHIBIT 8: Argenx: sources of Bernstein's OLD sales forecasts (\\$bn) by disease",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "66a591fccded5c37",
      "text": "Each sales 'wedge' represents a Vygart contribution unless otherwise stated.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "748ad7d79bd2c489",
      "text": "MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating Polyneuropathy; ITP = Immune Thrombocytopenia Purpura; TED = Thyroid Eye Disease; SJS = Sjogren's Syndrome; MMN = Multifocal Motor Neuropathy;",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "02b61b6093301e33",
      "text": "EXHIBIT 9: Argenx: sources of Bernstein's NEW sales forecasts (\\$bn) by disease",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6aaf2812e9f6ec8c",
      "text": "Each sales 'wedge' represents a Vygart contribution unless otherwise stated.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a0403498b7aa6a2a",
      "text": "MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3fbe71f59b47b84d",
      "text": "Polyneuropathy; ITP = Immune Thrombocytopenia Purpura; TED = Thyroid Eye",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "408dbcb72ef11040",
      "text": "Disease; SJS = Sjogren's Syndrome; MMN = Multifocal Motor Neuropathy;",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a7e815e7044b3b74",
      "text": "empa = emasiprubart Source: Company reports, Bernstein analysis and estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a11d18781fadad6c",
      "text": "empa = emasiprubart Source: Company reports, Bernstein analysis and estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "fa2f967166d0b6c1",
      "text": "During its 16/7/24 CMD Argenx indicated that it expects 50k patients to be treated with its medicines by 2030 (Exhibit 10). Considering management's strong execution since then we believe that this target is credible. However, our 2030 total revenue estimate of \\(\\) 12bn\\(which is\\) 23\\%\\(ahead of consensus (Bloomberg)) discounts 32k patients treated with Argenx's medicines. Hence, we do not believe that our new EPS estimates are too aggressive.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "af86ebf5859963b6",
      "text": "EXHIBIT 10: Argenx 2030 Vision",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ac6bcf42c85dc2f3",
      "text": "Source: Argenx CMD (16th July 2024)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "774fccaa7767285f",
      "text": "EXHIBIT 11:Non-IG competitive landscapes",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "53f563c557a59f9a",
      "text": "DiseaseStatusDrugCompanyMechanismPatent ExpiryLaunch2030 consMGApproved on 30/4/25 FiledNipocalimab UpilzinaJohnson &amp;amp; Johnson AmgenNeonatal Fc receptor (FcRn) antagonist B-lymphocyte antigen CD19 antibody2025 6/11/20326/30/20241,347 1,160Phase IIICemdisiran Gefurulimab Descartes-08 Mavenclad Fabhalta AtaciceptRegeneron AstraZeneca Cartesian Therapeutics Merck KGaA Novartis Vera TherapeuticsC-C chemokine receptor type 5 (CCR5) RNAi therapeutic Complement factor C5 inhibitor Chimeric antigen receptor T (CAR-T) cell therapy Adenosine deaminase inhibitor Complement factor B inhibitor B Lymphocyte stimulator (BLyS)2026 12/31/2026 10/16/2026 7/14/2034 12/31/20372026 12/31/2026 12/31/2027 2028 2028132 615 222 398 2,669 1,262CIPDPhase IIIRystiggo Rilipurbarb EnspryngUCB Sanofi Chugai PharmaceuticalNeonatal Fc receptor (FcRn) antagonist Serine protease C1 antibody Interleukin-6 (IL-6) receptor antagonist1/7/2035 12/31/2025 9/25/20291,063 140 190SJSPhase IIIDNTH103 Enspryng NipocalimabDianthus Chugai Pharmaceutical Johnson &amp;amp; JohnsonComplement factor C1 convertase (C3 convertase) inhibitor Interleukin-6 (IL-6) receptor antagonist Neonatal Fc receptor (FcRn) antagonist2027 2026503 207 1,347Phase IIIlanulumab Dazodalibep Vygart Orcenia Sotykut Dazodalibep Veldona NipocalimabNovartis Amgen argenx Bristol Myers Squibb AstraZeneca Ainos Johnson &amp;amp; JohnsonB-cell activating factor (BAFF) inhibitor CD40 regulator Neonatal Fc receptor (FcRn) antagonist T-cell inhibitor; T-Cell stimulant Tyrosine kinase (TYK) 2 inhibitor CD40 regulator Interferon (IFN) alpha regulator Neonatal Fc receptor (FcRn) antagonist12/31/2024 12/31/2034 12/31/2036 12/31/2026 11/7/2033 1/0/1900 4/30/203312/31/2026 12/31/2027 12/31/2028 12/31/2028 1,093 0 0 0 1,347619 142 8,871 2,829 1,093 0 0 0 1,347TEDPhase IIIBatoclimab Veligrotug VRDN-003 Enspryng Batoclimab VygartImmuvonant/Roviant Viridian Therapeutics Viridian Therapeutics Roche HanAll BioPharma argenxB Lymphocyte stimulator (BLyS); Tumour necrosis factor super Neonatal Fc receptor (FcRn) antagonist Insulin-like growth factor receptor 1 (IGF-1R) antibody Insulin-like growth factor receptor 1 (IGF-1R) antibody Interleukin-6 (IL-6) receptor antagonist Neonatal Fc receptor (FcRn) antagonist12/31/2037 3/31/2027 12/31/2026 9/25/2029 1/0/1900 12/31/2036943 1,009 552 207 0 8,871MyositisPhase IIIDazukibartPfizerInterferon (IFN) beta 1 inhibitor Janus kinase 1 (JAK1) inhibitor; Tyrosine kinase (TYK) 2 inhibitor12/31/202699MMNPhase IIIEmpasiprubart PlasmaCap IG KD-380argenx Evolve Biologics Meiji HoldingsComplement factor C1 inhibitor T-cell inhibitor Complement factor C5 antibody Passive immunisation (polyvalent immunoglobulin)2027 12/31/2026 3/31/2035 1/0/1900 1/0/1900 1/0/19001,212 2,829 3,646 0 0 0 0 8,871",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2f9736669ed1f556",
      "text": "IG = immunoglobulin; MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating Polyneuropathy; ITP = Immune Thrombocytopenia Purpura; TED = Thyroid Eye Disease; SJS = Sjogren's Syndrome; MMN = Multifocal Motor Neuropathy Source: Company reports, Bernstein analysis and estimates, EvaluatePharma",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "41ee6dbf992b0ba2",
      "text": "In our bull case scenario (Exhibit 12) we assume successful commercialization in each of the segments for Vygart and empasiprubart in which Argenx is now conducting phase 3 trials (Exhibit 9; Exhibit 13). In this instance, we project Vygart peak sales, group peak profitability and a Price Target of \\(25.5bn, 58\\%\\) and €1,377 respectively. We also forecast that 39k patients will be treated with Argenx's products in 2030.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "8da4908dcc57fca8",
      "text": "In our model, ARGX's aspiration of 50k patients receiving its drugs in 2030 (Exhibit 10) is equivalent to our Bull case scenario described above plus the 25k patient expansion in the US MG market driven by new entrants (Exhibit 6). Hence, if management achieves its aspiration our Price Target would more than double to €1,920 (Exhibit 12).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "80b6d677c3bf23ab",
      "text": "EXHIBIT 12: Bernstein scenario analysis ( \\(5m\\) unless otherwise stated)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3ee5d48d6dc33953",
      "text": "ScenarioPeak salesPeak margin2030 patients (k)Valuation/share (EUR)Bern Vygart assumptionsBern&#x27;empa&#x27; assumptionsBASE CASE17.945%32885100% probability: seropositive MG and CIDP; 60% probability: seronegative MG, ocular MG, ITP, TED, Myositis; 25% probability: Sjogren&#x27;s60% probability: CIDP, MMNBULL CASE25.558%391,377100% probability: seropositive MG, CIDP, seronegative MG, ocular MG, ITP, TED, Myositis, Sjogren&#x27;s100% probability: CIDP, MMNBEAR CASE10.131%27449100% probability: seropositive MG and CIDP0% probability: CIDP, MMNGUIDANCE HIT37.468%501,920In addition to bull case, Argenx treats 50k patients by 2030 as MG market expands in line with mgmt&#x27;s projectionsSame as bull case",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c5900bc7806c9620",
      "text": "MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating Polyneuropathy; ITP = Immune Thrombocytopenia Purpura; TED = Thyroid Eye Disease; SJS",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "408212b8ea58c0b5",
      "text": "= Sjogren&#x27;s Syndrome; MMN = Multifocal Motor Neuropathy; empa = empasipurbat Source: Company reports, Bernstein estimates",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0c9d1c98b6016dd4",
      "text": "We acknowledge that Argenx has executed well on the launch of Vygart in MG and CIDP. However, we note that management ceased development of this drug in Pemphigus Vulgaris (autoimmune skin condition) as its phase 3 trial here failed in 4Q23. The ADVANCE SC trial of Vygart in ITP (Immune Thrombocytopenia Purpura; low number of platelets (facilitate blood clotting) also failed on its primary endpoint during the same period.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "366cdbac069b78f7",
      "text": "Considering these pipeline disappointments we think it's reasonable to assume that, in the bear case, Vygart only generates sales in its existing FDA approved indications of MG and CIDP. Hence, in this scenario we project Vygart peak sales of \\(\\) 10bn\\(group peak profitability of\\) 31\\% \\(and a Price Target of\\) \\ \\(449\\) (Exhibit 12). Here we also forecast 27k patients will be treated with Argenx's products in 2030 vs management's 50k (Exhibit 10). But considering management's excellent execution since 2024 we think this bearish scenario is probably too extreme.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "05d2e576887eb44a",
      "text": "We expect Argenx to report eight phase 3 data read-outs between 2H25 and 2028 (Exhibit 13) of which six are in new indications. From a prevalence perspective, Thyroid Eye Disease (TED) and Sjogren's are by far the largest of these novel markets (Argenx estimates ca 100k addressable US populations in each). However, our forecasts for each of these segments are very conservative because of potential competition and disease heterogeneity (which increases clinical trial risk as identifying the right patients is difficult) respectively. However, as described above we believe that the risks to the Vygart life cycle management opportunities, in aggregate, are strongly skewed to the upside.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b242dcea7fe2b026",
      "text": "We note that two of the eight registrational milestones expected before the end of 2028 will be for the company's second most advanced drug empasipurbat. Moreover, on 16/9/25 Argenx will host an investor event which will focus on its third most advanced asset (ARGX- 119). This drug is in phase 1 and 2 in Congenital Myasthenic Syndromes (CMS; a hereditary neuromuscular disease unlike MG which is autoimmune (ie not inherited) and Amyotrophic Lateral Sclerosis; ALS- commonly known as motor neuron disease) respectively. In our view all of these milestones are relevant because they could increase investors' confidence in Argenx's ability to mitigate the impact of the Vygart Substance of Matter patent (the most robust intellectual property) expires in the US and Europe in March 2035 and August 2037 respectively.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b47a4edbdd4e12a8",
      "text": "EXHIBIT 13:Argenx late stage R6D milestones",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ef7bff9131e76ce0",
      "text": "DateIndication (drug)MilestoneCommentBern 2035e25-Aug-25Seronegative MG (Vvygart)Phase 3 read outHigh unmet &#x27;in-market&#x27; need according to physicians. Bernstein risk adjustment = 60%.1.82H25Switch CIDP (Vvygart)Phase 4 read outPlanned well in advance but helps case to displace IVIG. Bernstein risk adjustment = 60%3.61H26Ocular MG (Vvygart)Phase 3 read out80% of patients progress to generalised Myasthenia Gravis according to Argenx. Bernstein risk adjustment = 60%1.12H26MMN (empasiprubart)Phase 3 read outDifficult disease to diagnose but special committee formed to mitigate this risk. Weekly dosing like in CIDP. Bernstein risk adjustment = 60%1.02H26TED (Vvygart)Phase 3 read outFirst phase 3 to use prefilled syringe. But lots of competing trials with different MoAs. Weekly dosing like in CIDP. Bernstein risk adjustment = 60%0.82H26Myositis (Vvygart)Phase 3 read outWeekly dosing (like in CIDP). Adequately powered for all three subpopulations. Bernstein risk adjustment = 60%1.22H26ITP (Vvygart)Phase 3 read outSmaller and faster to run than prior two phase 3 trials. Primary endpoint also less stringent. Bernstein risk adjustment = 60%0.42027Sjögren&#x27;s (Vvygart)Phase 3 read outWeekly dosing like in CIDP. Bernstein risk adjustment = 25% due to high mis-diagnosis risk1.02028CIDP (empasiprubart)Phase 3 read out30% of patients didn&#x27;t respond to Vvygart in ADHERE phase 3 trial. Argenx will also run a placebo controlled phase 3 trial. Bernstein risk adjustment = 60%0.6",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ded1eb631ab2921f",
      "text": "MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating Polyneuropathy; ITP = Immune Thrombocytopenia Purpura; TED = Thyroid Eye Disease; MMN = Multifocal Motor Neuropathy; MoA = mechanism of action. 2028 timing CIDP empa read out is Bernstein's estimate Source: Company reports, Bernstein estimates",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ea270c453bf01e37",
      "text": "EXHIBIT 14: ARGX-119's mechanism of action: this drug boosts functioning of NMJs by improving AChR clustering",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "bbc99a2374ce5c12",
      "text": "NMJ = neuromuscular junction; AChR = Acetylcholine receptor, an integral membrane protein that responds to the binding of neurotransmitter acetylcholine Source: Argenx",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "739408baf9bd4cab",
      "text": "EXHIBIT 15: : Argenx EV/sales (rolling one-year forward)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8f28dc92b8c7295e",
      "text": "Source: Bloomberg, Bernstein analysis",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "53902bf9fcc21670",
      "text": "EXHIBIT 16: EV/sales: Argenx premium to US biotech peers",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d7668efe95475eb0",
      "text": "Peer group is Amgen, Biogen,Vertex, Regeneron, BioMarin, Gilead, Horizon, Incyte, Sarepta, United Therapeutics, Genmab, Alnylam, Beigene, BioNTech and Legend Biotech Source: Bloomberg, Bernstein analysis and estimates",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "b05ff37091edb8ae",
      "text": "To calculate our EV/EBITA valuation for Argenx (of €988; Exhibit 22) we continue to assume a \\(50\\%\\) premium to US biotech peers because of the superior growth which we project the company to deliver (Exhibit 18). Cutting this premium to \\(25\\%\\) would lower our Price Target from €885 to €800 (Exhibit 19).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "11cc55fbbed41f0c",
      "text": "For the large cap pharma stocks in Bernstein's EU biopharma coverage universe, our DCF's include perpetuity values which are calculated via the Net Present Value of the bottom- up free cash flow forecast at the end of the second decade (which is currently 2045). But considering that Argenx is a much younger company than the EU biopharma large caps, we assume that from 2037 (ie the first full calendar year after the Vygart patent expiry) up to and including 2045, Argenx's sales flat line and that it maintains a \\(39\\%\\) margin (vs \\(45\\%\\) in 2035). We also apply a perpetuity growth rate post 2045 of \\(0\\%\\) because we project that the company's net cash will be \\(26bn and\\) 46bn at the end of 2032 and 2035 respectively.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "8ca5e798809d2ca2",
      "text": "Although Argenx has much smaller R&D budget than the EU large caps, to be conservative the \\(8\\%\\) WACC which we are assuming in our Argenx DCF is line with what we use in EU large cap pharma. (Please refer to (Exhibit 20) for the sensitivity of our PT to our WACC assumption).",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9ba67b2cdc0d54c0",
      "text": "EXHIBIT 17: Argenx: drivers of change to Price Target (€)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f7e1d65cac0d9707",
      "text": "Argenx Price Target calculation (Eur)OldNew% changeCommentEV/EBITA (at 31/12/26)84298817%Still assumes 50% premium to peers due to above average sales growth but growth period extended to 2027-2029 from 2025-2027 to more appropriately represent growth profileDCF (at 31/12/26)52778148%Still assumes WACC of 8% and 0% perpetuity growthPrice target (simple average) (Euro)68588529%",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "a9c64bed0e852223",
      "text": "Source: Company reports, Bernstein estimates",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f3def147d4c0fabf",
      "text": "Our PT is increasing by \\(29\\%\\) to €885 (Exhibit 17) because the upgrades described above are supplemented by peer group multiple expansion and rolling over to year need 2026.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "235c73b4106e5210",
      "text": "At the current share price, our above consensus EPS estimates imply that Argenx trades at \\(1\\%\\) discount to peers in 2028 which widens to a \\(23\\%\\) discount in 2030 (Exhibit 21). Meanwhile, our PT of EUR885 implies a premium to peers of \\(54\\%\\) in 2028 which drops to \\(20\\%\\) by 2030 (Exhibit 21).",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5960c465d8346198",
      "text": "Our Argenx PT also implies a PE27 of \\(31x\\) which is the same as for Alnylam (ALNY (O) covered by William Pickering) - Exhibit 18. However, our PT implies a PE28 of \\(21x\\) which places the stock on the line of best fit if the analysis in Exhibit 18 is rolled over by 12 months. This \\(21x\\) PE28 also implies a \\(13\\%\\) discount to Alnylam (on Bloomberg consensus) despite EPS CAGRrs (28- 31) which are broadly similar ( \\(20\\%\\) for Argenx (on our estimates) vs \\(21\\%\\) for ALNY based on Bloomberg consensus). In our view this implied discount for Argenx is important because these stocks have similar outlying growth prospects within the biotech industry (Exhibit 18).",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5f0d445c8dfb6f8a",
      "text": "EXHIBIT 18: Biotech PE27 vs EPS CAGR (27-30e)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "733f0497c7a2503c",
      "text": "VRTX = Vertex; ALNY = Alnylam; AMGN = Amgen; ARGX = Argenx; GILD = Gilead; REGN = Regeneron; BMRN = BioMarin; GMAB = Genmab; BIIB = Biogen; UTHR = United Therapeutics; INCY = Incyte; SRPT = Sarepta Source: Company reports, Bernstein estimates (for Genmab), Bloomberg consensus for all the other stocks. Based on closing share prices on 27/8/25",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "db8ade24f0138027",
      "text": "EXHIBIT 19: Argenx PT sensitivity to premium to biotech peers",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "22cbe8c808b6a5c2",
      "text": "Red column illustrates the assumption used for the price target Source: Bernstein analysis and estimates",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e7ac3dc38761884b",
      "text": "EXHIBIT 20: Argenx PT sensitivity to WACC in DCF (€)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "44e5ce3d334ea9ab",
      "text": "Source: Company reports, Bernstein estimates",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e7e09e7da8762a34",
      "text": "EXHIBIT 21: PE multiples",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "109cecfc01041e66",
      "text": "SP \\(=\\) share price; PT \\(=\\) Bernstein Price Target; US biotech is market cap weighted average of Amgen, Biogen, Vertex, Regeneron, BioMarin, Gilead, Incyte, Sarepta, United Therapeutics, Genmab, BioNTech, Beigene, Alnylam, Legend",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e24cb97a98c41f84",
      "text": "Biotech Source: Company reports, Bernstein estimates",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "d3f053ec51102d61",
      "text": "EXHIBIT 22: Argenx EV/EBITA multiples based valuation (\\$m, except per share data and unless otherwise stated)",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "4c4be5d3a16a215c",
      "text": "2027e2028e2029ePremiumAverageEBITA2,5373,9105,072Sector multiple13.4x12.0x11.1xTarget multiple20.1x18.0x16.6x50%Enterprise value51,02170,32484,413Net debt/(cash) +Pensions(5,967.5)(8,242.0)(11,718.0)Equity value56,98878,56696,131Shares666767Equity value per share (in US$)8601,1781,4311,156Equity value per share (in EUR)988",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "95abd0f521d2ce72",
      "text": "Source: Company reports, Bernstein estimates",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "bd42590b393b0e53",
      "text": "EXHIBIT 23: Argenx discounted cash flow valuation (\\), except per share data and unless otherwise stated)",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "2bf5afde08eb5e93",
      "text": "2026e2027e2028e2029e2030e2031e2032e2033e2034e2035e2040e2045eSales5,0086,5218,62410,37911,99113,47514,63715,73016,83417,90414,75214,752% growth19%30%32%20%16%12%9%7%7%6%0%0%EBIT1,6132,5273,8995,0626,0516,8687,3357,6657,9208,0465,7535,753Margin32%39%45%49%50%39%50%49%47%45%39%39%Tax(285)(446)(689)(894)(1,069)(1,213)(1,296)(1,354)(1,399)(1,421)(1,016)(1,016)Tax rate (reported)-18%-18%-18%-18%-18.5%-18%-18%-18%-19%-18%-18%-18%NOPAT1,3282,0813,2114,1684,9825,6556,0396,3116,5216,6254,7374,737D&amp;amp;A27344353668095111128147121121as % of sales1%1%0%1%1%1%1%1%1%1%1%Working capital1,9432,6523,6684,5205,2805,9536,4316,8487,2487,6016,0116,011as % of sales39%41%43%44%44%44%44%44%43%42%41%41%Increase in WC3557091,015852760673477418400353--Net Capex48628299114128139150160171140140as % of sales1%1%1%1%1%1.5%1%1%1%1%1%Operating FCF9521,3432,1563,2704,1734,9335,5175,8546,0896,2494,7184,718Discount Factor100%93%86%79%74%68%63%58%54%50%34%23%NPV9521,2431,8482,5963,0673,3573,4763,4163,2903,1261,6061,093Sum NPV42,964Perpetuity value13,664Total EV56,628Net Debt/(cash)-3,508Pension &amp; provision2Market value60,135Diluted Shares66Per share price (USD)914Per share price (EUR)781",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "8aa6b651135dac1f",
      "text": "Source: Bernstein analysis and estimates",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9d643d38a864d9dc",
      "text": "EXHIBIT 24: **Argenx summary financials (US\\$, except per share data)**",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "44a0539037bc54a3",
      "text": "202320242025e2026e2027e2028e2029e2030e2031e2032e2033e2034e2035eP&LProduct net sales1,1912,1864,1354,9796,4748,56510,30911,91313,40014,56115,65116,75417,819Collaboration revenue364100000000Other operating income42627429476070787576788086Total revenues1,2692,2524,2095,0086,5218,62410,37911,99113,47514,63715,73016,83417,904Cost of sales-118-227-448-570-745-989-1,190-1,373-1,541-1,673-1,797-1,923-2,044Gross profit1,1512,0253,7614,4385,7767,6359,18910,61911,93412,96413,93314,91215,860Research and development expenses-859-983-1,342-1,543-1,774-2,041-2,347-2,699-3,103-3,569-4,104-4,720-5,428Selling, general and administrative expenses-712-1,055-1,221-1,282-1,474-1,696-1,780-1,869-1,963-2,061-2,164-2,272-2,386Loss from investment in JV-4-8-500000000Operating income (loss)-425-221,1931,6132,5273,8995,0626,0516,8687,3357,6657,9208,046Net Financial income/(expense)1061551511431582183104285697299021,0851,276Exchange gains/(losses)14-4876000000000Profit/(Loss) before taxes-304851,4201,7562,6854,1175,3726,4797,4378,0648,5679,0049,322Income tax (expense)/benefit9748-251-310-474-727-949-1,144-1,314-1,425-1,513-1,591-1,647Net Income/(Loss)-2958331,1701,4462,2103,3904,4235,3346,1236,6397,0537,4147,675Diluted EPS(in&#36;)-5.1612.7817.7821.8333.1350.4765.0577.0187.8895.29101.24106.40110.16Balance sheetCash and cash equivalents2,0491,5001,6682,7074,1316,4069,88314,35719,70425,76532,29939,21246,433Financial assets-current1,1311,8791,8791,8791,8791,8781,8791,8791,8791,8701,8791,8791,879Trade and other receivables4979041,6912,0112,6193,4644,1684,8165,4125,8796,3176,7617,191Inventories3114077619061,1791,5601,8772,1682,4372,6472,8443,0443,238Other current assets137193254286336397446497553610674744822Total current assets4,1244,8836,2537,78910,14413,70418,25223,71829,98436,77944,01351,64059,563Property, plant and equipment23446596135185240299358413462504538Intangible assets12518117116115114013012011099897968Other non-current assets2711,0941,0891,0891,0891,0891,0881,0891,0891,0891,0871,0891,089Total non-current assets4191,3191,3261,3471,3751,4141,4601,5081,5571,6011,6401,6721,695Total assets4,5426,2037,5799,13611,51915,11919,71225,22631,54138,38145,65353,31261,258Total equity4,0985,4986,6618,10710,31713,70718,13023,46429,58836,22743,28150,69458,369Total non-current liabilities22343535363637383839404041Trade and other payables4146508649741,1461,3551,5251,7041,8952,0952,3132,5572,828Others92020202020202020202020Total current liabilities4236708849941,1661,3751,5451,7241,9152,1152,3332,5772,848Total Equity and Liabilities4,5426,2037,5799,13611,51915,11919,71225,22631,54138,38145,65353,31261,258Cashflow statementOperating profit/(loss)-425-221,1931,6132,5273,8995,0626,0516,8687,3357,6657,9208,046Depreciation & amortisation111182227344353668095111128147Others2382395011111111Movements in current assets/liabilities-762351,2211,6412,5613,9435,1166,1176,9487,4307,7778,0498,194Movements in non-current assets/liabilities-232-329-988-387-759-1,076-901-812-728-535-481-470-431Cash flows (used in)/from operating activities-7740000000000Interest paid-0-00000000000Income taxes paid-388-251-310-474-727-949-1,144-1,314-1,425-1,513-1,591-1,647Net cash flow (used in)/from operating activities-422-82-189431,3282,1393,2664,1614,9065,4705,7825,9886,117Purchase of intangible assets-43-670000000000Purchase of property, plant and equipment-1-2-40-48-62-82-99-114-128-139-150-160-171Others352-6491511431582183104285697299021,0851,276Net cash flow (used in)/from investing activities308-71811195961362113144415907529241,105Net cash flow (used in)/from financing activities1,3372800000000000Net increase (decrease) in cash & cash equivalents1,223-520931,0391,4242,2753,4774,4755,3476,0606,5356,9127,222Cash and cash equivalents at the beginning of the8012,0491,5001,6682,7074,1316,4069,88314,35719,70425,76532,29939,212periodExchange gains/(losses) on cash & cash equivalents23-2876000000000Cash and cash equivalents at the end of the period2,0471,5001,6682,7074,1316,4069,88314,35719,70425,76532,29939,21246,433",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "9c3e6d7b3d8bfc0e",
      "text": "Source: Company reports, Bernstein estimates",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "6692848c56134bb9",
      "text": "26 AugTTMAdjusted EPSAdjusted P/E (x)RatingCurClosingPricePriceTargetRel. Perf.Cur2024A2025E2026E2024A2025E2026ETickerUSD12.7817.7821.8354.639.231.9ARGX.BBOEUR598.60885.0022.4%OLD685.007.7411.79EDM1,471.58",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "f327f9c55a2128ed",
      "text": "**PRICE TARGET CHANGE / ESTIMATE CHANGE IN BOLD**",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "94a5fe52a3a83db9",
      "text": "O - Outperform, M - Market-Perform, U - Underperform, NR - Not Rated, CS - Coverage Suspended",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "45853b11702af930",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "77e032abf1fa083e",
      "text": "References to \"Bernstein\" or the \"Firm\" in these disclosures relate to the following entities: Bernstein Institutional Services LLC (April 1, 2024 onwards), Sanford C. Bernstein & Co., LLC (pre April 1, 2024), Bernstein Autonomous LLP, BSG France S.A. (April 1, 2024 onwards), Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH00006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社).",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "e8393a1829bd47ba",
      "text": "On April 1, 2024, Société Générale (SG) and AllianceBernstein, LP. (AB) completed a transaction that created a new joint venture in which their respective cash equities and research businesses operate in a new business combination. Although their respective ownership percentages in the joint venture differ between North America and the rest of the world, the creation, production and publication of research is handled collaboratively on a global basis across the two research brands, \"Bernstein\" and \"Autonomous\". Unless specifically noted otherwise, for purposes of these disclosures, references to Bernstein's \"affiliates\" relate to both SG and AB and their respective affiliates.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "26cb292a0a68a933",
      "text": "Our price target of €885 is the simple average of two approaches: i) 2027- 29e EV/EBITA multiples, which assume a \\(50\\%\\) premium to the US biotech peer group average, and ii) a DCF using an \\(8\\%\\) WACC and \\(0\\%\\) perpetuity growth rate. We think this strikes the right balance between the short and long term.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "06552506ca158da8",
      "text": "Downside risk: (1) If Vygart fails to get approval in new indications 2) empasiprubart doesn't get approved 3) The CEO (who was also a co- founder) leaves the company.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "2c5e02dbff8c2daa",
      "text": "The Bernstein brand rates stocks based on forecasts of relative performance for the next 12 months versus the S&P 500 for stocks listed on the U.S. and Canadian exchanges, versus the Bloomberg Europe Developed Markets Large and Mid Cap Price Return Index (EDM) for stocks listed on the European exchanges and emerging markets exchanges outside of the Asia Pacific region, versus the Bloomberg Japan Large and Mid Cap Price Return Index USD (JP) for stocks listed on the Japanese exchanges, and versus the Bloomberg Asia ex- Japan Large and Mid Cap Price Return Index (ASIAX) for stocks listed on the Asian (ex- Japan) exchanges - unless otherwise specified.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "baad5598be6d8e21",
      "text": "The Bernstein brand has three categories of ratings:",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a573f33c0b2072ea",
      "text": "- Outperform: Stock will outpace the market index by more than 15 pp- Market-Perform: Stock will perform in line with the market index to within +/-15 pp- Underperform: Stock will trail the performance of the market index by more than 15 pp",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "079cf30dd537815c",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a8f230308cc64555",
      "text": "Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "03e14687445633fb",
      "text": "Not Covered (NC) denotes companies that are not under coverage.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "6963f0fd58931de7",
      "text": "The Autonomous brand rates stocks as indicated below. As our benchmarks we use the Bloomberg Europe 500 Banks And Financial Services Index (BEBANKS) and Bloomberg Europe Dev Mkt Financials Large and Mid Cap Price Ret Index EUR (EDMFI) index for developed European banks and Payments, the Bloomberg Europe 500 Insurance Index (BEINSUR) for European insurers, the S&P 500 and S&P Financials for US banks and Payments coverage, S5LIFE for US Insurance, the S&P Insurance Select Industry (SPSIINS) for US Non-Life Insurers coverage, and the Bloomberg Emerging Markets Financials Large, Mid and Small Cap Price Return Index (EMLSF) for emerging market banks and insurers and Payments. Ratings are stated relative to the sector (not the market).",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2a46cea20ec1198d",
      "text": "The Autonomous brand has three categories of ratings:",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "4d4ccc8359094686",
      "text": "Outperform (OP): Stock will outpace the relevant index by more than 10 pp- Neutral (N): Stock will perform in line with the market index to within \\(+ / - 10\\) pp- Underperform (UP): Stock will trail the performance of the relevant index by more than 10 pp",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "afaecb8b37a626e2",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "d43fcbbd7c2c32c7",
      "text": "Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "cdca1aa64960c23e",
      "text": "Those denoted as 'Feature' (e.g., Feature Outperform FOP, Feature Under Outperform FUP) are our core ideas. Not Covered (NC) denotes companies that are not under coverage.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "73766498a68663fa",
      "text": "For both brands, recommendations are based on a 12- month time horizon.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "56601546a957b98b",
      "text": "DISTRIBUTION OF EQUITY RATINGS/INVESTMENT BANKING SERVICES",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "20fa6fe5da6cab6b",
      "text": "RatingMarket Abuse Regulation (MAR) and FINRA Rule 2241 classificationCountPercentCount*Percent*OutperformBUY58551.27%11018.80%Market-Perform (Bernstein Brand)HOLD40735.67%7618.67%Neutral (Autonomous Brand)UnderperformSELL14913.06%2013.42%",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "dc412c260e86472e",
      "text": "\\* These figures represent the number and percentage of companies in each category to whom affiliates of Bernstein and Autonomous provided investment banking services. As of June 30, 2025. All figures are updated quarterly.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "09bce7fc38ce1585",
      "text": "Certain affiliates of Bernstein act as market maker or liquidity provider in the equities securities of: Argenx SE.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "f2af127b636cb246",
      "text": "The legal entity(ies) employing the analyst(s) listed in this report, and their location, can be determined by the country code of their phone number, as follows:",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "5b95ec60e422f174",
      "text": "+1 Bernstein Institutional Services LLC; New York, New York, USA+44 Bernstein Autonomous LLP; London UK+33 BSG France S.A.; Paris, France+34 BSG France S.A.; Madrid, Spain+41 Bernstein Autonomous LLP; Geneva, Switzerland+49 BSG France S.A.; Frankfurt, Germany+91 Sanford C. Bernstein (India) Private Limited; Mumbai, India+852 Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司; Hong Kong, China+65 Sanford C. Bernstein (Singapore) Private Limited; Singapore+81 Sanford C. Bernstein Japan KK; Tokyo, Japan",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "51334567b9da8e9c",
      "text": "Where this report has been prepared by research analyst(s) employed by a non- US affiliate, such analyst(s), is/are (unless otherwise expressly noted below) not registered as associated persons of Bernstein Institutional Services LLC or any other SEC- registered broker- dealer and are not licensed or qualified as research analysts with FINRA. Accordingly, such analyst(s) may not be subject to FINRA's restrictions regarding (among other things) communications by research analysts with a subject company, interactions between research analysts and investment banking personnel, participation by research analysts in solicitation and marketing activities relating to investment banking transactions, public appearances by research analysts, and trading securities held by a research analyst account.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "70d40f6ada5992ad",
      "text": "Each research analyst listed in this report, who is primarily responsible for the preparation of the content of this report, certifies that all of the views expressed in this publication accurately reflect that analyst's personal views about any and all of the subject securities or issuers and that no part of that analyst's compensation was, is, or will be, directly or indirectly, related to the specific",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "e6c383741ea8c272",
      "text": "recommendations or views in this publication.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "ad6dc0919dce5a6a",
      "text": "It is at the sole discretion of the Firm as to when to initiate, update and cease research coverage. The Firm has established, maintains and relies on information barriers to control the flow of information contained in one or more areas (i.e., the private side) within the Firm, and into other areas, units, groups or affiliates (i.e., public side) of the Firm.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "3e99e38c38e215d1",
      "text": "Separate branding is maintained for \"Bernstein\" and \"Autonomous\" research products.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "5c9c38b77fb544d5",
      "text": "- Bernstein produces a number of different types of research products including, among others, fundamental analysis and quantitative analysis under both the \"Autonomous\" and \"Bernstein\" brands. Recommendations contained within one type of research product may differ from recommendations contained within other types of research products, whether as a result of differing time horizons, methodologies or otherwise. Furthermore, views or recommendations within a research product issued under one brand may differ from views or recommendations under the same type of research product issued under the other brand. The Research Ratings System for the two brands and other information related to those Rating Systems are included in the previous section.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "fcfccef1d4c2de71",
      "text": "- Autonomous operates as a separate business unit within the following entities: Bernstein Institutional Services LLC, Bernstein Autonomous LLP, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and Sanford C. Bernstein (India) Private Limited. For information relating to \"Autonomous\" branded products (including certain Sales materials) please visit: www.autonomous.com. For information relating to Bernstein branded products please visit: www.bernsteinresearch.com.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "aeec12606cc4bdd2",
      "text": "Analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration, productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to, generating investment banking revenues.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "5866c03762d7468a",
      "text": "This report has been produced by an independent analyst as defined in Article 3 (1)(34)(i) of EU 596/2014 Market Abuse Regulation (\"MAR\") and the same article of MAR as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "202fe9c564d37c53",
      "text": "To our readers in the United States: Bernstein Institutional Services LLC, a broker- dealer registered with the U.S. Securities and Exchange Commission (\"SEC\") and a member of the U.S. Financial Industry Regulatory Authority, Inc. (\"FINRA\") is distributing this publication in the United States and accepts responsibility for its contents. Where this material contains an analysis of debt product(s), such material is intended only for institutional investors and is not subject to the US independence and disclosure standards applicable to debt research prepared for retail investors.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "f3fba56623e8b12a",
      "text": "Bernstein Institutional Services LLC may act as principal for its own account or as agent for another person (including an affiliate) in sales or purchases of any security which is a subject of this report. This report does not purport to meet the objectives or needs of any specific individuals, entities or accounts.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "f97f4782f0052d86",
      "text": "To our readers in Canada: If this publication pertains to a Canadian domiciled company, it is being distributed in Canada by Sanford C. Bernstein (Canada) Limited, which is licensed and regulated by the Canadian Investment Regulatory Organization. If the publication pertains to a non- Canadian domiciled company, it is being distributed by Bernstein Institutional Services LLC, which is licensed and regulated by both the SEC and FINRA, into Canada under the International Dealers Exemption.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "8fdc7586f3ff7409",
      "text": "This document may not be passed onto any person in Canada unless that person qualifies as \"permitted client\" as defined in Section 1.1 of NI 31- 103.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "0d143dcfe7916911",
      "text": "To our readers in Brazil: This report has been prepared by Bernstein Institutional Services LLC, and Banco BTG Pactual S.A. (\"BTG\") is responsible for the distribution of this report in Brazil.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "cb002f8597e7abe8",
      "text": "To readers in the United Kingdom: This publication has been issued or approved for issue in the United Kingdom by Bernstein Autonomous LLP, authorised and regulated by the Financial Conduct Authority and located at 60 London Wall, London EC2M 5SH, +44 (0)20- 7170- 5000. Registered in England & Wales No OC343985.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "8586c201ec338424",
      "text": "This document is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the \"Financial Promotion Order\"), (ii) are persons falling within Article 49(2)(a) to (d) (\"high net worth companies, unincorporated associations, etc.\") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "135bf202c7293efd",
      "text": "to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as \"relevant persons\"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "e012c3503a889759",
      "text": "To our readers in the member states of the EEA: This publication is being distributed by BSG France SA, which is authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and Autorité des Marchés Financiers (AMF).",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "951ec566fb79a985",
      "text": "To our readers in Hong Kong: This publication is being distributed in Hong Kong by Sanford C. Bernstein (Hong Kong) Limited, a company in Hong Kong, which is licensed and regulated by the Hong Kong Securities and Futures Commission (Central Entity No. AXC846) to carry out Type 4 (Advising on Securities) regulated activities and subject to the licensing conditions mentioned in the SFC Public Register (https://www.sfc.hk/publicregWeb/corp/AXC846/details)). This publication is solely for professional investors, as defined in the Securities and Futures Ordinance (Cap. 571).",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "19a9488cdb6eb598",
      "text": "To our readers in Singapore: This publication is being distributed in Singapore by Sanford C. Bernstein (Singapore) Private Limited, only to accredited investors or institutional investors, as defined in the Securities and Futures Act 2001 of Singapore (\"SFA\"). Recipients in Singapore should contact Sanford C. Bernstein (Singapore) Private Limited in respect of matters arising from, or in connection with, this publication. Sanford C. Bernstein (Singapore) Private Limited is regulated by the Monetary Authority of Singapore and licensed under the SFA as a capital markets services licence holder for dealing in capital markets products that are securities and collective investment schemes and an exempt financial adviser for advising on, issuing and promulgating analyses and reports on securities. Sanford C. Bernstein (Singapore) Private Limited is registered in Singapore with Company Registration No. 20213710W and located at One Raffles Quay, #27- 11 South Tower, Singapore 048583, +65- 6230- 4612.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "dc8ebb3561c15d8c",
      "text": "To our readers in the People's Republic of China: The securities referred to in this document are not being offered or sold and may not be offered or sold, directly or indirectly, in the People's Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan, the \"PRC\") in contravention of any applicable laws of the PRC.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "c24c2f5c5b08f79f",
      "text": "This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC to any person to whom it is unlawful to make the offer or solicitation in the PRC.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "ee6a7a22a392e205",
      "text": "We do not represent that this document may be lawfully distributed, or that any securities may be lawfully offered, in compliance with any applicable registration or other requirements in the PRC, or pursuant to an exemption available thereunder, or assume any responsibility for facilitating any such distribution or offering. In particular, no action has been taken by us which would permit a public offering of any securities or distribution of this document in the PRC. Accordingly, the securities are not being offered or sold within the PRC by means of this document or any other document. Neither this document nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "c3c9ef519c4325e5",
      "text": "To our readers in Japan: This publication is being distributed in Japan by Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社), which is registered in Japan as a Financial Instruments Business Operator with the Kanto Local Finance Bureau (registration number: The Director- General of Kanto Local Finance Bureau (FIBO) No.3387) and regulated by the Financial Services Agency. It is also a member of Japan Investment Advisers Association. This publication is solely for qualified institutional investors in Japan only, as defined in Article 2, paragraph (3), items (i) of the Financial Instruments and Exchange Act.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "4a1bf761f40dba6a",
      "text": "For the institutional client readers in Japan who have been granted access to the Bernstein website by Daiwa Securities Group Inc. (\"Daiwa\"), your access to this document should not be construed as meaning that Bernstein is providing you with investment advice for any purposes. Whilst Bernstein has prepared this document, your relationship is, and will remain with, Daiwa, and Bernstein has neither any contractual relationship with you nor any obligations towards you.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "d8814685e137fb42",
      "text": "To our readers in Australia: Sanford C. Bernstein (Hong Kong) Limited, a company in Hong Kong, which is licensed and regulated by the Monetary Authority of Singapore and licensed under the SFA as a capital markets services licence holder for dealing in capital markets products that are securities and collective investment schemes and an exempt financial adviser for advising on, issuing and promulgating analyses and reports on securities. Sanford C. Bernstein (Singapore) Private Limited is registered in Singapore with Company Registration No. 20213710W and located at One Raffles Quay, #27- 11 South Tower, Singapore 048583, +65- 6230- 4612.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "3424c30248aa1545",
      "text": "- providing financial product advice;",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "e699795a85d03415",
      "text": "- dealing in a financial product;",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "516b1b745afa5a39",
      "text": "- making a market for a financial product; and",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "8ee90f5de5c4fe7c",
      "text": "- providing a custodial or depository service.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "8985384a92a8f7a8",
      "text": "To our readers in India: This publication is being distributed in India by Sanford C. Bernstein (India) Private Limited (SCB India) which is licensed and regulated by Securities and Exchange Board of India (\"SEBI\") as a research analyst entity under the SEBI (Research Analyst) Regulations, 2014, having registration no. INH000006378 and as a stock broker having registration no. INZ000213537. SCB India is currently engaged in the business of providing research and stock broking services. Please refer to www.bernsteinresearch.in for more information.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "b23c40f10d8611c2",
      "text": "- SCB India is a Private limited company incorporated under the Companies Act, 2013, on April 12, 2017 bearing corporate identification number U65999MH2017FTC293762, and registered office at Level 3A, 4th Floor, First International Financial Centre, Plot Nos C-54 and C-55, G Block, Near CBI Office, Bandra Kurla Complex, Bandra (East), Mumbai 400098, Maharashtra, India (Phone No: +91-22-68421401).",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "1fc320e3fbc84e08",
      "text": "- SCB India does not have any disciplinary history as on the date of this report.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "9f216e35f5126d68",
      "text": "- Except as noted above, SCB India and/or its Associates (i.e., affiliates/group companies), the Research Analysts authoring this report, and their relatives",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "bf2fe829a20e4bc9",
      "text": "- do not have any financial interest in the subject company- do not have actual/beneficial ownership of one percent or more in securities of the subject company;- is not engaged in any investment banking activities for Indian companies, as such;- have not managed or co-managed a public offering in the past twelve months for any Indian companies;- have not received any compensation for investment banking services or merchant banking services from the subject company in the past 12 months;- have not received compensation for brokerage services from the subject company in the past twelve months;- have not received any compensation or other benefits from the subject company or third party related to the specific recommendations or views in this report; and- do not currently, but may in the future, act as a market maker in the financial instruments of the companies covered in the report.- do not have any conflict of interest in the subject company as of the date of this report.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "dd8dc93dc3539d95",
      "text": "- Except as noted above, the subject company has not been a client of SCB India during twelve months preceding the date of distribution of this research report. Neither SCB India nor its Associates (i.e., affiliates/group companies) have received compensation for products or services other than investment banking, merchant banking or brokerage services from the subject company in the past twelve months.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "0b9a40a31baa44e6",
      "text": "- The principal research analyst(s) who prepared this report, members of the analysts' team, and members of their households are not an officer, director, employee or advisory board member of the companies covered in the report.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "4ce86304f13f0279",
      "text": "- The investor charter of SCB India is available on its website and may be accessed at Sanford C. Bernstein (India) Private Limited (bernsteinresearch.in)",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "3ba46b65b18bc663",
      "text": "- Disclaimer: Registration granted by SEBI, and certification from NISM, is in no way a guarantee of performance of the intermediary or provide any assurance of returns to investors. Investments in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "d41312a846b9bdd2",
      "text": "To our readers in Switzerland: This document is provided in Switzerland by or through Bernstein Autonomous LLP, and is provided only to qualified investors as defined in article 10 of the Swiss Collective Investment Scheme Act (\"CISA\") and related provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations. The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives on the Independence of Financial Research issued by the Swiss Bankers Association (SBA) in January 2008.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "7a925f7e6e342960",
      "text": "To our readers in the Middle East: Bernstein Autonomous LLP, DIFC branch has its principal office at Gate Village 06, DIFC, Dubai, UAE. Bernstein Autonomous LLP, DIFC branch is regulated by the Dubai Financial Services Authority (DFSA) with the registration number F008549 and is provisioned for Arranging Deals in Investments and Advising on Financial Products. All communications and services are directed at Professional Clients and Market Counterparties only (as defined in the DFSA rulebook). Persons other than Professional Clients and Market Counterparties, such as Retail Clients, are not the intended recipients of our communications or services.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "641f2fd7ff296d8e",
      "text": "All research publications are disseminated to our clients through posting on the firm's password protected websites, bernsteinresearch.com and autonomous.com. Certain, but not all, research publications are also made available to clients through third- party vendors or redistributed to clients through alternate electronic means as a convenience.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "0c62e3f824de8bdc",
      "text": "This publication has been published and distributed in accordance with the Firm's policy for management of conflicts of interest in investment research, a copy of which is available from Bernstein Institutional Services LLC, Director of Compliance, 245 Park Avenue, New York, NY 10167. Additional disclosures and information regarding Bernstein's business are available on our website www.bernsteinresearch.com.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "a28f572a9bf396a5",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject any of the entities referenced herein or any of their subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction. This publication is based upon public sources we believe to be reliable, but no representation is made by us that the publication is accurate or complete. We do not undertake to advise you of any change in the reported information or in the opinions herein. This publication was prepared and issued by entity referred to herein for distribution to eligible counterparties or professional clients. This publication is not an offer to buy or sell any security, and it does not constitute investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with their professional advisors in light of their specific circumstances. The value of investments may fluctuate, and investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to exchange rate movements. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "f3740bc1af12e2d9",
      "text": "This report is directed to and intended only for our clients who are \"eligible counterparties\", \"professional clients\", \"institutional investors\" and/or \"professional investors\" as defined by the aforementioned regulators, and must not be redistributed to retail clients as defined by the aforementioned regulators. Retail clients who receive this report should note that the services of the entities noted herein are not available to them and should not rely on the material herein to make an investment decision. The result of such act will not hold the entities noted herein liable for any loss thus incurred as the entities noted herein are not registered/ authorised/ licensed to deal with retail clients and will not enter into any contractual agreement/arrangement with retail clients. This report is provided subject to the terms and conditions of any agreement that the clients may have entered into with the entities noted herein. All research reports are disseminated on a simultaneous basis to eligible clients through electronic publication to our client portal. The information is private and confidential and for the use of the clients only.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "39b31462a2333f19",
      "text": "This report has been prepared for information purposes only and is based on current public information that we consider reliable, but the entities noted herein do not warrant or represent (express or implied) as to the sources of information or data contained herein are accurate, complete, not misleading or as to its fitness for the purpose intended even though the entities noted herein rely on reputable or trustworthy data providers, it should not be relied upon as such. Opinions expressed are the author(s)' current opinions as of the date appearing on the material only and we do not undertake to advise you of any change in the reported information or in the opinions herein.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "e6a91ce8d1cde62f",
      "text": "This publication was prepared and issued by the entity referred to herein for distribution to eligible counterparties or professional clients. The information in this report is intended for general circulation and does not constitute an offer to buy or sell any security, investment, legal or tax advice nor a personal recommendation, as defined by any of the aforementioned regulators. It does not take into account the particular investment objectives, financial situations, or needs of individual investors. The report has not been reviewed by any of the aforementioned regulators and does not represent any official recommendation from the aforementioned regulators. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with advice sought from a financial adviser regarding the suitability of the investment product, taking into account the",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "c973175601ccba9b",
      "text": "specific investment objectives, financial situation or particular needs of any recipient of the recommendation, before the recipient makes a commitment to purchase the investment product.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "0f14e6d57c1f6c33",
      "text": "The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The information in this report does not constitute, or form part of, any offer to sell or issue, or any offer to purchase or subscribe for shares, or to induce engage in any other investment activity. The value of any securities or financial instruments mentioned in this report may fluctuate subject to market conditions. Information about past performance of an investment is not necessarily a guide to, indicative of, or assurance of future performance. Estimates of future performance mentioned by the research analyst in this report are based on assumptions that may not be realized due to unforeseen factors like market volatility/fluctuation. In relation to securities or financial instruments denominated in a foreign currency other than the clients' home currency, movements in exchange rates will have an effect on the value, either favorable or unfavorable. Before acting on any recommendations in this report, recipients should consider the appropriateness of investing in the subject securities or financial instruments mentioned in this report and, if necessary, seek for independent professional advice.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "afb46a9af01c980f",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject the entities noted herein to any regulation or licensing requirement within such jurisdiction.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "bb22fe0cc0041e5b",
      "text": "No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社). All rights reserved. The trademarks and service marks contained herein are the property of their respective owners. Any unauthorized use or disclosure is strictly prohibited. The entities noted herein may pursue legal action if the unauthorized use results in any defamation and/or reputational risk to the entities noted herein and research published under the Bernstein and Autonomous brands.",
      "page": 24,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "af0234deee25916b",
      "name": "Adjusted EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7e2d4425303bea59",
      "name": "Administrative Regions",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6afac77b7140b4ce",
      "name": "Advisers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "837beceac3a7a8f5",
      "name": "Ainos Johnson",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "abd269e48dcde94e",
      "name": "Although Argenx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "75698043ed89d07d",
      "name": "Amyotrophic Lateral",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b1868656493e0753",
      "name": "Argenx CMD",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e2d4839d0b1d6575",
      "name": "Argenx DCF",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "45fd3931d283edb8",
      "name": "Argenx EV",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d38d8f366de2708d",
      "name": "Argenx PT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "76fe587fd87ba637",
      "name": "Argenx Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "628c6c952bc2160b",
      "name": "Argenx SE",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bf450f9d7cbb2e1d",
      "name": "Arranging Deals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "18ff676d9d8cf555",
      "name": "Autonomous Brand",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c160d65049f4dfd5",
      "name": "Autonomous LLP",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9ff62f2014c91e7",
      "name": "BB Close",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5a165af17b571df3",
      "name": "BSG France",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f0c4286f4d23d3fd",
      "name": "Banco BTG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc2c783d2ec3346b",
      "name": "Bandra Kurla",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "f9b153d2dfc4e80b",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-23",
              "Mar-23",
              "May-23",
              "Jul-23",
              "Sep-23",
              "Nov-23",
              "Jan-24",
              "Mar-24",
              "May-24",
              "Jul-24",
              "Sep-24",
              "Nov-24",
              "Jan-25",
              "Mar-25",
              "May-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "x",
            "range": {
              "min": 0,
              "max": 25
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "x",
            "values": [
              22,
              19.5,
              17,
              15,
              22.5,
              19,
              14.5,
              10,
              11.5,
              9,
              11,
              11.5,
              11,
              9,
              7.5,
              8.5
            ]
          }
        ],
        "figure_id": "082cd32181321262",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "other",
        "title": "COMMITMENT TO OUR TRANSFORMATION MISSION",
        "page": 6,
        "axes": {},
        "series": [
          {
            "name": "New Molecules in Phase 3",
            "unit": "count",
            "values": [
              5
            ]
          },
          {
            "name": "Labeled Indications",
            "unit": "count",
            "values": [
              10
            ]
          },
          {
            "name": "Patients on Treatment",
            "unit": "count",
            "values": [
              50000
            ]
          }
        ],
        "figure_id": "ee87f5a4370e8322",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "other",
        "title": "Mechanism of Action of ARGX-119 in Neuromuscular Junction",
        "page": 10,
        "axes": null,
        "series": [
          {
            "name": "MuSK phosphorylates downstream signaling components",
            "unit": null,
            "values": [
              {
                "step": 1,
                "description": "MuSK phosphorylates downstream signaling components"
              }
            ]
          },
          {
            "name": "MuSK-induced clustering of AChRs and muscle contraction upon Acetylcholine binding",
            "unit": null,
            "values": [
              {
                "step": 2,
                "description": "MuSK-induced clustering of AChRs and muscle contraction upon Acetylcholine binding"
              }
            ]
          },
          {
            "name": "Retrograde signal to stimulate presynaptic differentiation",
            "unit": null,
            "values": [
              {
                "step": 3,
                "description": "Retrograde signal to stimulate presynaptic differentiation"
              }
            ]
          }
        ],
        "figure_id": "3a0bd5f29ea446c6",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "area",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2022",
              "2023",
              "2024",
              "2025",
              "2026",
              "2027",
              "2028",
              "2029",
              "2030",
              "2031",
              "2032",
              "2033",
              "2034",
              "2035"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 18
            }
          }
        },
        "series": [
          {
            "name": "MG",
            "unit": null,
            "values": [
              0.2,
              0.8,
              1.8,
              2.8,
              3.5,
              5.5,
              6.5,
              6.8,
              7.0,
              7.1,
              7.2,
              7.3,
              7.4,
              7.5
            ]
          },
          {
            "name": "ITP",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "CIDP",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "TED",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "SJS",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "Myositis",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "MMN (empa)",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          },
          {
            "name": "CIDP (empa)",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0
            ]
          }
        ],
        "figure_id": "5cf98839d30cb0bb",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "scatter",
        "title": null,
        "page": 12,
        "axes": {
          "x": {
            "type": "value",
            "labels": "EPS CAGR 2027-30e",
            "unit": "%",
            "range": {
              "min": -20,
              "max": 40
            }
          },
          "y": {
            "type": "value",
            "labels": "2027e P/E",
            "unit": "x",
            "range": {
              "min": 0,
              "max": 35
            }
          }
        },
        "series": [
          {
            "name": "INCY",
            "values": [
              {
                "x": -15,
                "y": 10
              }
            ]
          },
          {
            "name": "BIIB",
            "values": [
              {
                "x": -2,
                "y": 8.5
              }
            ]
          },
          {
            "name": "SRPT",
            "values": [
              {
                "x": 0,
                "y": 4.5
              }
            ]
          },
          {
            "name": "AMGN",
            "values": [
              {
                "x": 5,
                "y": 13
              }
            ]
          },
          {
            "name": "REGN",
            "values": [
              {
                "x": 6,
                "y": 7.5
              }
            ]
          },
          {
            "name": "VRTX",
            "values": [
              {
                "x": 9,
                "y": 17.5
              }
            ]
          },
          {
            "name": "UTHR",
            "values": [
              {
                "x": 10,
                "y": 9
              }
            ]
          },
          {
            "name": "BMRN",
            "values": [
              {
                "x": 10.5,
                "y": 10.5
              }
            ]
          },
          {
            "name": "GILD",
            "values": [
              {
                "x": 12,
                "y": 14
              }
            ]
          },
          {
            "name": "GMAB",
            "values": [
              {
                "x": 15,
                "y": 14.5
              }
            ]
          },
          {
            "name": "ALNY",
            "values": [
              {
                "x": 22,
                "y": 29
              }
            ]
          },
          {
            "name": "ARGX",
            "values": [
              {
                "x": 32,
                "y": 21
              }
            ]
          }
        ],
        "figure_id": "4028dce5a27af248",
        "provenance": {
          "page": 12
        }
      },
      {
        "type": "bar",
        "title": null,
        "page": 12,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "25%",
              "50%",
              "75%",
              "100%"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 1000
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": null,
            "values": [
              820,
              890,
              950,
              1000
            ]
          }
        ],
        "figure_id": "e42824a831cf32d0",
        "provenance": {
          "page": 12
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 1,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "08/24",
              "11/24",
              "02/25",
              "05/25",
              "08/25"
            ]
          },
          "y": {
            "unit": "€",
            "range": {
              "min": 450,
              "max": 700
            }
          }
        },
        "series": [
          {
            "name": "Series 1",
            "unit": "€",
            "values": [
              530,
              470,
              550,
              450,
              580,
              620,
              580,
              640
            ]
          },
          {
            "name": "Series 2",
            "unit": null,
            "values": [
              1250,
              1350,
              1500,
              1200,
              1400,
              1500,
              1300,
              1450
            ]
          }
        ],
        "figure_id": "a90b2a5d4298f1d2",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2027e",
              "2028e",
              "2029e",
              "2030e"
            ]
          },
          "y": {
            "unit": "x",
            "range": {
              "min": 5.0,
              "max": 35.0
            }
          }
        },
        "series": [
          {
            "name": "ARGX (SP / Bern e)",
            "unit": "x",
            "values": [
              21.0,
              15.5,
              10.5,
              9.5
            ]
          },
          {
            "name": "ARGX (PT / Bern e)",
            "unit": "x",
            "values": [
              31.0,
              20.5,
              15.5,
              13.5
            ]
          },
          {
            "name": "ARGX (SP / cons e)",
            "unit": "x",
            "values": [
              21.5,
              16.0,
              14.5,
              12.0
            ]
          },
          {
            "name": "US biotech (SP / cons e)",
            "unit": "x",
            "values": [
              14.8,
              13.5,
              12.0,
              11.5
            ]
          }
        ],
        "figure_id": "81a039708082cb95",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "6%",
              "7%",
              "8%",
              "9%",
              "10%"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 800,
              "max": 1050
            }
          }
        },
        "series": [
          {
            "name": "Data Points",
            "unit": null,
            "values": [
              {
                "x": "6%",
                "y": 1015
              },
              {
                "x": "7%",
                "y": 941
              },
              {
                "x": "8%",
                "y": 885
              },
              {
                "x": "9%",
                "y": 841
              },
              {
                "x": "10%",
                "y": 807
              }
            ]
          }
        ],
        "figure_id": "6e69ab4cf2d9f5fb",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "area",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2022",
              "2023",
              "2024",
              "2025",
              "2026",
              "2027",
              "2028",
              "2029",
              "2030",
              "2031",
              "2032",
              "2033",
              "2034",
              "2035"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 18
            }
          }
        },
        "series": [
          {
            "name": "MG",
            "unit": null,
            "values": [
              0.2,
              0.8,
              1.8,
              3.5,
              4.8,
              6.0,
              7.0,
              7.8,
              8.5,
              9.0,
              9.4,
              9.7,
              9.9,
              10.0
            ]
          },
          {
            "name": "ITP",
            "unit": null,
            "values": [
              0.0,
              0.1,
              0.2,
              0.3,
              0.4,
              0.5,
              0.6,
              0.7,
              0.8,
              0.9,
              1.0,
              1.1,
              1.2,
              1.3
            ]
          },
          {
            "name": "CIDP",
            "unit": null,
            "values": [
              0.0,
              0.1,
              0.2,
              0.3,
              0.4,
              0.5,
              0.6,
              0.7,
              0.8,
              0.9,
              1.0,
              1.1,
              1.2,
              1.3
            ]
          },
          {
            "name": "TED",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.1,
              0.1,
              0.2,
              0.2,
              0.3,
              0.3,
              0.4,
              0.4,
              0.5,
              0.5,
              0.6,
              0.6
            ]
          },
          {
            "name": "SJS",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.1,
              0.1,
              0.1,
              0.2,
              0.2,
              0.2,
              0.3,
              0.3,
              0.3,
              0.4,
              0.4
            ]
          },
          {
            "name": "Myositis",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.1,
              0.1,
              0.1,
              0.1,
              0.2,
              0.2,
              0.2,
              0.2,
              0.3,
              0.3
            ]
          },
          {
            "name": "MMN (empa)",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "CIDP (empa)",
            "unit": null,
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.0,
              0.1,
              0.1
            ]
          }
        ],
        "figure_id": "004835acfde1ce51",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "other",
        "title": "VYVGART Hytrulo Injection Information",
        "page": 3,
        "axes": null,
        "series": [
          {
            "name": "NDC",
            "unit": null,
            "values": [
              "73475-3102-3"
            ]
          },
          {
            "name": "Drug Name",
            "unit": null,
            "values": [
              "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)"
            ]
          },
          {
            "name": "Total Dose",
            "unit": "mg and units/mL",
            "values": [
              "1,008 mg and 11,200 units/5.6 mL"
            ]
          },
          {
            "name": "Concentration",
            "unit": "mg and units/mL",
            "values": [
              "180 mg and 2,000 units/mL"
            ]
          },
          {
            "name": "Administration",
            "unit": null,
            "values": [
              "For subcutaneous injection over 30 to 90 seconds",
              "One single-dose vial",
              "Discard unused portion",
              "Must be administered by a healthcare provider"
            ]
          }
        ],
        "figure_id": "5d2979cd0c0b1e4a",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-23",
              "Mar-23",
              "May-23",
              "Jul-23",
              "Sep-23",
              "Nov-23",
              "Jan-24",
              "Mar-24",
              "May-24",
              "Jul-24",
              "Sep-24",
              "Nov-24",
              "Jan-25",
              "Mar-25",
              "May-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 250
            }
          }
        },
        "series": [
          {
            "name": "Value",
            "unit": "%",
            "values": [
              210,
              175,
              160,
              190,
              200,
              160,
              70,
              55,
              40,
              50,
              60,
              70,
              90,
              50,
              30,
              20
            ]
          }
        ],
        "figure_id": "d2a581a2afe43424",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": "Argenx SE (ARGX.BB) Rating History for Bernstein as of 08/27/2025",
        "page": 20,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "€",
            "range": {
              "min": 100,
              "max": 800
            }
          }
        },
        "series": [
          {
            "name": "Closing Price",
            "unit": "€",
            "values": [
              370,
              350,
              380,
              450,
              400,
              350,
              300,
              400,
              500,
              600,
              500,
              580
            ]
          },
          {
            "name": "Price Target",
            "unit": "€",
            "values": [
              165,
              165,
              165,
              165,
              165,
              165,
              155,
              155,
              155,
              155,
              755,
              685
            ]
          }
        ],
        "figure_id": "c501e80f7841702d",
        "provenance": {
          "page": 20
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Feb-22",
              "May-22",
              "Aug-22",
              "Nov-22",
              "Feb-23",
              "May-23",
              "Aug-23",
              "Nov-23",
              "Feb-24",
              "May-24",
              "Aug-24",
              "Nov-24",
              "Feb-25",
              "May-25",
              "Aug-25",
              "Nov-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 900
            }
          }
        },
        "series": [
          {
            "name": "Bern new Trx",
            "unit": null,
            "values": [
              5,
              10,
              20,
              50,
              70,
              60,
              75,
              90,
              100,
              130,
              150,
              200,
              300,
              770,
              580,
              550
            ]
          },
          {
            "name": "Bern old Trx",
            "unit": null,
            "values": [
              5,
              10,
              20,
              40,
              60,
              65,
              70,
              80,
              95,
              110,
              130,
              180,
              280,
              320,
              330,
              370
            ]
          }
        ],
        "figure_id": "e937aa707a39a3c2",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-23",
              "Mar-23",
              "May-23",
              "Jul-23",
              "Sep-23",
              "Nov-23",
              "Jan-24",
              "Mar-24",
              "May-24",
              "Jul-24",
              "Sep-24",
              "Nov-24",
              "Jan-25",
              "Mar-25",
              "May-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 45
            }
          }
        },
        "series": [
          {
            "name": "FY25",
            "unit": null,
            "values": [
              8.5,
              8,
              8.5,
              9.5,
              7,
              6,
              5,
              4,
              4,
              4.5,
              6,
              8,
              9.5,
              11,
              12.5,
              15
            ]
          },
          {
            "name": "FY26",
            "unit": null,
            "values": [
              22,
              21,
              22.5,
              22,
              19,
              17,
              14,
              11,
              10,
              10.5,
              16,
              14,
              18,
              20,
              21,
              25
            ]
          },
          {
            "name": "FY27",
            "unit": null,
            "values": [
              37,
              32,
              37,
              35,
              31,
              27,
              23,
              20,
              20,
              23,
              27,
              29,
              30,
              28,
              29,
              34
            ]
          }
        ],
        "figure_id": "66c29331bf81a5e1",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "waterfall",
        "title": "Path to 60K Addressable Patients",
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Addressable Market at Launch",
              "Seronegative",
              "Ocular",
              "Growth in Biologics Share of Market",
              "Total Addressable Market in 2030"
            ]
          },
          "y": {
            "unit": "Patients",
            "range": {
              "min": 0,
              "max": 60000
            }
          }
        },
        "series": [
          {
            "name": "U.S. Addressable MG Patients",
            "unit": "Patients",
            "values": [
              17000,
              11000,
              7000,
              25000,
              60000
            ]
          }
        ],
        "figure_id": "b300fc40f4078afb",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "fd63f2d633f8db9e",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "**ARGX (0): why's there still much more to play for (£885)?** Our upgraded EPS forecasts are upto 25% &gt; consensus (Bloomberg) as we think Myasthenia Gravis (MG; neuromuscular autoimmune disease) ma",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e9bcbbf380c99e78",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "on and Vygvart life cycle management and both underappreciated. The risks to our new £885 PT (up by 29%) are also positively skewed (+117% if ARGX hits its 2030 guidance of 50k patients treated with i",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "efe1b021697b0544",
        "value": 1.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent and both underappreciated. The risks to our new £885 PT (up by 29%) are also positively skewed (+117% if ARGX hits its 2030 guidance of 50k patients treated with its drugs vs -49% if the entire pi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "458c123c8622df1e",
        "value": -0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o positively skewed (+117% if ARGX hits its 2030 guidance of 50k patients treated with its drugs vs -49% if the entire pipeline fails). Hence, we identify eight potential R&D catalysts pre year-end 20",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e5eeae5976a05ff2",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "potential R&D catalysts pre year-end 2028. What's more, our new £885 PT implies a PE30 of 13x for a 20% premium to peers which is robust on our regression analysis due to ARGX's leading prospects. **W",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e591722204e5c2b8",
        "value": 1.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "scounts 39k ARGX treated patients in 2030 and implies upside to the share price (s/p) and our PT of 126% and 56% respectively. But we also calculate that the 2030 guidance of 50k ARGX treated patients",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "80b97c66cf7efa61",
        "value": 0.56,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9k ARGX treated patients in 2030 and implies upside to the share price (s/p) and our PT of 126% and 56% respectively. But we also calculate that the 2030 guidance of 50k ARGX treated patients implies ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9f7709e2f068dd9c",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "erive only 27k ARGX treated patients. In this instance, the downside to the s/p and our PT would be 26% and 49% respectively. But considering ARGX's excellent execution since the 4Q23 pipeline nadir w",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ed246716dafda721",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ly 27k ARGX treated patients. In this instance, the downside to the s/p and our PT would be 26% and 49% respectively. But considering ARGX's excellent execution since the 4Q23 pipeline nadir we believ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4e06fe0c435c9051",
        "value": -1.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t's changed and why we do forecast so much upside surprise?** We're raising our 2025-2027e EPS by 27-130% due to higher than expected US Vygvart volumes April-July 2025 driven by the better launch of ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "210ac607f5d1301e",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Pre Filled Syringe;allows for home use without a nurse). Our new 2025-2034e EPS are thus now upto 25% &gt;consensus as we don't believe that 'the market' is adequately discounting the potential for V",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c9d531dd6ee9c847",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "hink the stock is cheap?** Our PT is still the average of '27-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (fr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "45fbaf58242a37ac",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ltiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our PT is increasing",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8a4e6ccf01e17aa2",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our PT is increasing by 29% to £885 as our upgrades are a",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a08634ac6c4d0db0",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "erpetuity growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our PT is increasing by 29% to £885 as our upgrades are augmented by peer group multiple expansion and rolling over. <table>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b7f6607a04a53078",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "se Date 26 Aug 2025 ARGX.BB Close Price (EUR) 598.60 Price Target (EUR) 885.00 Upside/(Downside) 48% 52-Week Range 658.00/456.30 EDM 1,471.58 FYE Dec Div Yield NA Market Cap (EUR) (M) 37,528 EV",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e196e4ed16101ccc",
        "value": 885.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "t ![Figure 0-0](images/0_0.jpg) **ARGX.BB** **ARGX (0): why's there still much more to play for (£885)?** Our upgraded EPS forecasts are upto 25% &gt; consensus (Bloomberg) as we think Myasthenia Grav",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cd6077375f01cf16",
        "value": 885.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "market expansion and Vygvart life cycle management and both underappreciated. The risks to our new £885 PT (up by 29%) are also positively skewed (+117% if ARGX hits its 2030 guidance of 50k patients ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "30972472f7b6b115",
        "value": 885.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "ne fails). Hence, we identify eight potential R&D catalysts pre year-end 2028. What's more, our new £885 PT implies a PE30 of 13x for a 20% premium to peers which is robust on our regression analysis ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "be3ea242b18965c2",
        "value": 1920.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "lso calculate that the 2030 guidance of 50k ARGX treated patients implies the shares would be worth £1,920.Conversely, in our bear case if Vygvart only generates sales in its two current segments, we ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7d4c5cc9238bb46b",
        "value": 842.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "and why do we think the stock is cheap?** Our PT is still the average of '27-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpet",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "6bfe9a152c4162e9",
        "value": 988.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "o we think the stock is cheap?** Our PT is still the average of '27-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity grow",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "fae7f0ad71d7cb25",
        "value": 527.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "age of '27-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (from 2045) and 8% WACC (same as for EU large cap Phar",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "30a477ddd6782ac7",
        "value": 781.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "7-29 EV/EBITA multiples (£842-&gt;£988; 50% premium to US biotech peers retained) and DCF (£527-&gt;£781; unchanged 0% perpetuity growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "87c182b2ca83936f",
        "value": 885.0,
        "unit": "£",
        "metric_type": "currency",
        "context": "ty growth (from 2045) and 8% WACC (same as for EU large cap Pharma). Our PT is increasing by 29% to £885 as our upgrades are augmented by peer group multiple expansion and rolling over. <table><tr><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "230487bdc672588c",
        "value": 1.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>77.01</td><td>87.88</td><td>95.29</td><td>101.24</td><td>106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "074b2966f5e7216c",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>87.88</td><td>95.29</td><td>101.24</td><td>106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "148aceb56dbb7f4f",
        "value": 0.27,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>95.29</td><td>101.24</td><td>106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>C",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "bb99269f5cd1edac",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>101.24</td><td>106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "50ded3ef2c877d69",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "24</td><td>106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48<",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6d7f43e8943f2639",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "106.40</td></tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48</td><td>25.",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "b0bf6c84d5de05c2",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48</td><td>25.02</td><td>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "be0023158e6d822e",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>% change</td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48</td><td>25.02</td><td>34.36</td><",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ce5c6db388eb0842",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>130%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48</td><td>25.02</td><td>34.36</td><td>45.26</t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "e016294e3b0a63f2",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>85%</td><td>27%</td><td>9%</td><td>4%</td><td>4%</td><td>5%</td><td>6%</td><td>7%</td><td>10%</td></tr><tr><td>Consensus</td><td>15.48</td><td>25.02</td><td>34.36</td><td>45.26</td><td>51.98",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2604558fac8d2016",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>63.14</td><td>72.96</td><td>81.45</td><td>90.73</td><td>89.54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f4fd48d869ec17d3",
        "value": -0.13,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>72.96</td><td>81.45</td><td>90.73</td><td>89.54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0e033d4a447d5efa",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>81.45</td><td>90.73</td><td>89.54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "55526441fda98c45",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>90.73</td><td>89.54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "1e50645283bb185a",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>89.54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "58314d73841b5afb",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "54</td></tr><tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein estimates an",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "029142604701d76a",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>% variance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein estimates and analysis, ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "20d7ae918577aad3",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "riance</td><td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein estimates and analysis, Bloomberg fo",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "e8377311eedef3ce",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>15%</td><td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein estimates and analysis, Bloomberg for consensus ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "209758eee1d1c56c",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-13%</td><td>-4%</td><td>12%</td><td>25%</td><td>22%</td><td>20%</td><td>17%</td><td>12%</td><td>19%</td></tr></table> Source: Bernstein estimates and analysis, Bloomberg for consensus We are incre",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "fc528aea4e027a64",
        "value": 1.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "imates and analysis, Bloomberg for consensus We are increasing our 2025- 2027 EPS forecasts by 27- 130% (Exhibit 1) due to the higher than expected realized Vygvart volumes in the US in its two FDA ap",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d44dcc2cdd3c1d24",
        "value": 1377.0,
        "unit": "€",
        "metric_type": "currency",
        "context": ", we project Vygart peak sales, group peak profitability and a Price Target of \\(25.5bn, 58\\%\\) and €1,377 respectively. We also forecast that 39k patients will be treated with Argenx's products in 20",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "83bffb9ae4a60dc0",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ssumptions</td><td>Bern&#x27;empa&#x27; assumptions</td></tr><tr><td>BASE CASE</td><td>17.9</td><td>45%</td><td>32</td><td>885</td><td>100% probability: seropositive MG and CIDP; 60% probability: sero",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "05320f78ae5ba11c",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "x27; assumptions</td></tr><tr><td>BASE CASE</td><td>17.9</td><td>45%</td><td>32</td><td>885</td><td>100% probability: seropositive MG and CIDP; 60% probability: seronegative MG, ocular MG, ITP, TED, M",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "02d772c70606f3cd",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>17.9</td><td>45%</td><td>32</td><td>885</td><td>100% probability: seropositive MG and CIDP; 60% probability: seronegative MG, ocular MG, ITP, TED, Myositis; 25% probability: Sjogren&#x27;s</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "fb5c1ef56de79dda",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ability: seropositive MG and CIDP; 60% probability: seronegative MG, ocular MG, ITP, TED, Myositis; 25% probability: Sjogren&#x27;s</td><td>60% probability: CIDP, MMN</td></tr><tr><td>BULL CASE</td><t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f5e07f9568025a1f",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "robability: seronegative MG, ocular MG, ITP, TED, Myositis; 25% probability: Sjogren&#x27;s</td><td>60% probability: CIDP, MMN</td></tr><tr><td>BULL CASE</td><td>25.5</td><td>58%</td><td>39</td><td>1,",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "fe3932387d510fad",
        "value": 0.58,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ": Sjogren&#x27;s</td><td>60% probability: CIDP, MMN</td></tr><tr><td>BULL CASE</td><td>25.5</td><td>58%</td><td>39</td><td>1,377</td><td>100% probability: seropositive MG, CIDP, seronegative MG, ocula",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "75003a34f5756a03",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ity: CIDP, MMN</td></tr><tr><td>BULL CASE</td><td>25.5</td><td>58%</td><td>39</td><td>1,377</td><td>100% probability: seropositive MG, CIDP, seronegative MG, ocular MG, ITP, TED, Myositis, Sjogren&#x2",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b227ba899450500e",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lity: seropositive MG, CIDP, seronegative MG, ocular MG, ITP, TED, Myositis, Sjogren&#x27;s</td><td>100% probability: CIDP, MMN</td></tr><tr><td>BEAR CASE</td><td>10.1</td><td>31%</td><td>27</td><td>4",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "bf329cafcb7830c4",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Sjogren&#x27;s</td><td>100% probability: CIDP, MMN</td></tr><tr><td>BEAR CASE</td><td>10.1</td><td>31%</td><td>27</td><td>449</td><td>100% probability: seropositive MG and CIDP</td><td>0% probability:",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "bea18289c4ab3d0e",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ility: CIDP, MMN</td></tr><tr><td>BEAR CASE</td><td>10.1</td><td>31%</td><td>27</td><td>449</td><td>100% probability: seropositive MG and CIDP</td><td>0% probability: CIDP, MMN</td></tr><tr><td>GUIDAN",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "6343b3a1f66462b2",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">10.1</td><td>31%</td><td>27</td><td>449</td><td>100% probability: seropositive MG and CIDP</td><td>0% probability: CIDP, MMN</td></tr><tr><td>GUIDANCE HIT</td><td>37.4</td><td>68%</td><td>50</td><td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "ce6352de4de43fd5",
        "value": 0.68,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ve MG and CIDP</td><td>0% probability: CIDP, MMN</td></tr><tr><td>GUIDANCE HIT</td><td>37.4</td><td>68%</td><td>50</td><td>1,920</td><td>In addition to bull case, Argenx treats 50k patients by 2030 as",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "600b1a542f50f860",
        "value": 1920.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "Exhibit 6). Hence, if management achieves its aspiration our Price Target would more than double to €1,920 (Exhibit 12). EXHIBIT 12: Bernstein scenario analysis ( \\(5m\\) unless otherwise stated) <tabl",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "46171e830ff7a58c",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>High unmet &#x27;in-market&#x27; need according to physicians. Bernstein risk adjustment = 60%.</td><td>1.8</td></tr><tr><td>2H25</td><td>Switch CIDP (Vvygart)</td><td>Phase 4 read out</td><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e8dad98d82afe6a9",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ad out</td><td>Planned well in advance but helps case to displace IVIG. Bernstein risk adjustment = 60%</td><td>3.6</td></tr><tr><td>1H26</td><td>Ocular MG (Vvygart)</td><td>Phase 3 read out</td><td>8",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "0c2f29d28aca8d1a",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "60%</td><td>3.6</td></tr><tr><td>1H26</td><td>Ocular MG (Vvygart)</td><td>Phase 3 read out</td><td>80% of patients progress to generalised Myasthenia Gravis according to Argenx. Bernstein risk adjustm",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f8ee32d565881505",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "patients progress to generalised Myasthenia Gravis according to Argenx. Bernstein risk adjustment = 60%</td><td>1.1</td></tr><tr><td>2H26</td><td>MMN (empasiprubart)</td><td>Phase 3 read out</td><td>D",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "4776c12de443d433",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ial committee formed to mitigate this risk. Weekly dosing like in CIDP. Bernstein risk adjustment = 60%</td><td>1.0</td></tr><tr><td>2H26</td><td>TED (Vvygart)</td><td>Phase 3 read out</td><td>First p",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "69d13ee729726c16",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ts of competing trials with different MoAs. Weekly dosing like in CIDP. Bernstein risk adjustment = 60%</td><td>0.8</td></tr><tr><td>2H26</td><td>Myositis (Vvygart)</td><td>Phase 3 read out</td><td>We",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "684908d86b707d20",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "dosing (like in CIDP). Adequately powered for all three subpopulations. Bernstein risk adjustment = 60%</td><td>1.2</td></tr><tr><td>2H26</td><td>ITP (Vvygart)</td><td>Phase 3 read out</td><td>Smaller",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "208523f939303a6f",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "un than prior two phase 3 trials. Primary endpoint also less stringent. Bernstein risk adjustment = 60%</td><td>0.4</td></tr><tr><td>2027</td><td>Sjögren&#x27;s (Vvygart)</td><td>Phase 3 read out</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "74212fc99f1b4233",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(Vvygart)</td><td>Phase 3 read out</td><td>Weekly dosing like in CIDP. Bernstein risk adjustment = 25% due to high mis-diagnosis risk</td><td>1.0</td></tr><tr><td>2028</td><td>CIDP (empasiprubart)</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "2bff93c8fd9b1dd7",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "isk</td><td>1.0</td></tr><tr><td>2028</td><td>CIDP (empasiprubart)</td><td>Phase 3 read out</td><td>30% of patients didn&#x27;t respond to Vvygart in ADHERE phase 3 trial. Argenx will also run a place",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e5d6687791fbbdec",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "phase 3 trial. Argenx will also run a placebo controlled phase 3 trial. Bernstein risk adjustment = 60%</td><td>0.6</td></tr></table> MG = Myasthenia Gravis; CIDP = Chronic Inflammatory Demyelinating ",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7212dc9213a5b1ce",
        "value": 0.17,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>% change</td><td>Comment</td></tr><tr><td>EV/EBITA (at 31/12/26)</td><td>842</td><td>988</td><td>17%</td><td>Still assumes 50% premium to peers due to above average sales growth but growth period e",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "c76be3983eef1232",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t</td></tr><tr><td>EV/EBITA (at 31/12/26)</td><td>842</td><td>988</td><td>17%</td><td>Still assumes 50% premium to peers due to above average sales growth but growth period extended to 2027-2029 from ",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "2f788678cebcb764",
        "value": 0.48,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "riately represent growth profile</td></tr><tr><td>DCF (at 31/12/26)</td><td>527</td><td>781</td><td>48%</td><td>Still assumes WACC of 8% and 0% perpetuity growth</td></tr><tr><td>Price target (simple ",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "7cb034021a01c5b8",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>DCF (at 31/12/26)</td><td>527</td><td>781</td><td>48%</td><td>Still assumes WACC of 8% and 0% perpetuity growth</td></tr><tr><td>Price target (simple average) (Euro)</td><td>685</td><t",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ad795a5481fa249a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>DCF (at 31/12/26)</td><td>527</td><td>781</td><td>48%</td><td>Still assumes WACC of 8% and 0% perpetuity growth</td></tr><tr><td>Price target (simple average) (Euro)</td><td>685</td><td>885</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "cc96402f3ade6c35",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "etuity growth</td></tr><tr><td>Price target (simple average) (Euro)</td><td>685</td><td>885</td><td>29%</td><td></td></tr></table> Source: Company reports, Bernstein estimates<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "58464231570d8f80",
        "value": 988.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "erg, Bernstein analysis and estimates </center> To calculate our EV/EBITA valuation for Argenx (of €988; Exhibit 22) we continue to assume a \\(50\\%\\) premium to US biotech peers because of the superio",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "6acb8c2f0a1658dd",
        "value": 885.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "company to deliver (Exhibit 18). Cutting this premium to \\(25\\%\\) would lower our Price Target from €885 to €800 (Exhibit 19). For the large cap pharma stocks in Bernstein's EU biopharma coverage univ",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "acaf32916e486d7a",
        "value": 800.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "to deliver (Exhibit 18). Cutting this premium to \\(25\\%\\) would lower our Price Target from €885 to €800 (Exhibit 19). For the large cap pharma stocks in Bernstein's EU biopharma coverage universe, ou",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ed7b4169a2876375",
        "value": 885.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "Our PT is increasing by \\(29\\%\\) to €885 (Exhibit 17) because the upgrades described above are supplemented by peer group multiple expansion",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "58715d39a0d1730c",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td></tr><tr><td>Target multiple</td><td>20.1x</td><td>18.0x</td><td>16.6x</td><td>50%</td><td></td></tr><tr><td>Enterprise value</td><td>51,021</td><td>70,324</td><td>84,413</td><td>",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "4a263308aa5a98b1",
        "value": 0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5,730</td><td>16,834</td><td>17,904</td><td>14,752</td><td>14,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3eccb4daec289bd3",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>16,834</td><td>17,904</td><td>14,752</td><td>14,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3c6bf51c7c225c35",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>17,904</td><td>14,752</td><td>14,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "2895069316c8e6ca",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>14,752</td><td>14,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1930734256274d24",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "52</td><td>14,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>E",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "ad3e34451d06d088",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4,752</td></tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "bc57653291848b59",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a6d6e67139f8c54c",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "% growth</td><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><td>2,527</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c9ae26a910f79a88",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>19%</td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><td>2,527</td><td>3,899<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "bc52f8d998696ea3",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>30%</td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><td>2,527</td><td>3,899</td><td>5,0",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "ee8ee36bee16fd5e",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>32%</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><td>2,527</td><td>3,899</td><td>5,062</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "b1286bc9891ad760",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>20%</td><td>16%</td><td>12%</td><td>9%</td><td>7%</td><td>7%</td><td>6%</td><td>0%</td><td>0%</td></tr><tr><td>EBIT</td><td>1,613</td><td>2,527</td><td>3,899</td><td>5,062</td><td>6,051</td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "16a475d111ec5899",
        "value": 0.32,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>7,665</td><td>7,920</td><td>8,046</td><td>5,753</td><td>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "4f30a3b0e9df0c39",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>7,920</td><td>8,046</td><td>5,753</td><td>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3868c71ea348f9b1",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>8,046</td><td>5,753</td><td>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "fe2e7a5a419a5fe5",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "046</td><td>5,753</td><td>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "9c7ab48608b27652",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5,753</td><td>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "2ce359f60ca87fb1",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5,753</td></tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "11d0a8c30fbeaf58",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "dbe9f7f7118904fe",
        "value": 0.49,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Margin</td><td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</td><td>(446)",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "7d221e609e1b69d1",
        "value": 0.47,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>32%</td><td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</td><td>(446)</td><td>(68",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "ac27cd6a1eab6b6f",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>39%</td><td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</td><td>(446)</td><td>(689)</td><td>(",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "59d5c6e781117543",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</td><td>(446)</td><td>(689)</td><td>(894)</td><td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "0ba9f407c271e5b4",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>49%</td><td>50%</td><td>39%</td><td>50%</td><td>49%</td><td>47%</td><td>45%</td><td>39%</td><td>39%</td></tr><tr><td>Tax</td><td>(285)</td><td>(446)</td><td>(689)</td><td>(894)</td><td>(1,069)</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "7a78e382d5697376",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1,399)</td><td>(1,421)</td><td>(1,016)</td><td>(1,016)</td></tr><tr><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "0ae669f7e28cd575",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>(1,421)</td><td>(1,016)</td><td>(1,016)</td></tr><tr><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a2cb2c456a8376ac",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>(1,016)</td><td>(1,016)</td></tr><tr><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "33bca7a3fd58a88e",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(1,016)</td></tr><tr><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "f704b22499893ec5",
        "value": -0.185,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6)</td></tr><tr><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "a6141660775c19cf",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Tax rate (reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "29fb5dc66cc9605e",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(reported)</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "e334929d22510c18",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>1,328</td><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c8c3318047f35b57",
        "value": -0.19,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-18%</td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>1,328</td><td>2,081</td><",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "e334929d22510c18",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-18%</td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>1,328</td><td>2,081</td><td>3,211</td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1172b37b041841bc",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-18%</td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>1,328</td><td>2,081</td><td>3,211</td><td>4,168</td",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "935bd1b895b4154d",
        "value": -0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-18.5%</td><td>-18%</td><td>-18%</td><td>-18%</td><td>-19%</td><td>-18%</td><td>-18%</td><td>-18%</td></tr><tr><td>NOPAT</td><td>1,328</td><td>2,081</td><td>3,211</td><td>4,168</td><td>4,982</t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "9ca35bf57c2e7494",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>111</td><td>128</td><td>147</td><td>121</td><td>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "bffe463f9f7527b4",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>128</td><td>147</td><td>121</td><td>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1aead03194d1dcf3",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "28</td><td>147</td><td>121</td><td>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "3eb57004f7de9e3c",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "147</td><td>121</td><td>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><t",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "1f31aecd6d6a3494",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">121</td><td>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Worki",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c5af8eb1c9c8e63d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>121</td></tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c9121afaff0a30a6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital</td><td>1,9",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "b1685ce7ade2fba7",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">as % of sales</td><td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital</td><td>1,943</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "eba34beddd8f2515",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1%</td><td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital</td><td>1,943</td><td>2,652</td><td>3,668<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "8c56d1f901da2111",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1%</td><td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital</td><td>1,943</td><td>2,652</td><td>3,668</td><td>4,5",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "17e0f2008df1582f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>0%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td>1%</td><td></td><td>1%</td><td>1%</td><td>1%</td></tr><tr><td>Working capital</td><td>1,943</td><td>2,652</td><td>3,668</td><td>4,520</td><td>",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "d9bda9634e030996",
        "value": 0.39,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",848</td><td>7,248</td><td>7,601</td><td>6,011</td><td>6,011</td></tr><tr><td>as % of sales</td><td>39%</td><td>41%</td><td>43%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>43%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "b57117dc29e81fa4",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">7,248</td><td>7,601</td><td>6,011</td><td>6,011</td></tr><tr><td>as % of sales</td><td>39%</td><td>41%</td><td>43%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>43%</td><td>42%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "5be3b68d1e1859c7",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>7,601</td><td>6,011</td><td>6,011</td></tr><tr><td>as % of sales</td><td>39%</td><td>41%</td><td>43%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>44%</td><td>43%</td><td>42%</td><td>41%<",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "c12f42e12bddcd8e",
        "value": 0.22399999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>ARGX.BB</td><td></td><td>O</td><td>EUR</td><td>598.60</td><td></td><td>885.00</td><td>22.4%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>OLD</td><td></",
        "provenance": {
          "page": 16
        }
      },
      {
        "num_id": "ff17d918557eb392",
        "value": 885.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "nd AB and their respective affiliates. ## VALUATION METHODOLOGY ## Argenx SE Our price target of €885 is the simple average of two approaches: i) 2027- 29e EV/EBITA multiples, which assume a \\(50\\%\\) ",
        "provenance": {
          "page": 17
        }
      },
      {
        "num_id": "46c9ce07d2c38123",
        "value": 0.5127,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Percent</td><td>Count*</td><td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td>HOLD</td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "b7d8de782d24131e",
        "value": 0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td>HOLD</td><td>407</td><td>35.67%</td",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "421ba5699d20ff4b",
        "value": 0.3567,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td>HOLD</td><td>407</td><td>35.67%</td><td>76</td><td>18.67%</td></tr><tr><td>Neutral (Autonomous Brand)</td><td></td><td></td><",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "45b6e452676bd556",
        "value": 0.1867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Market-Perform (Bernstein Brand)</td><td>HOLD</td><td>407</td><td>35.67%</td><td>76</td><td>18.67%</td></tr><tr><td>Neutral (Autonomous Brand)</td><td></td><td></td><td></td><td></td><td></td>",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "42ca8f5952a6e781",
        "value": 0.1306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td><td></td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percent",
        "provenance": {
          "page": 18
        }
      },
      {
        "num_id": "20670a39122e7d0d",
        "value": 0.13419999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percentage of companies in each c",
        "provenance": {
          "page": 18
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 17,
      "tables_count": 0,
      "numerical_data_count": 140,
      "passages_count": 195,
      "entities_count": 20
    }
  }
}